Search Results - "Dietlein, M."

Guidelines for radioiodine therapy of differentiated thyroid cancer by Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., Bombardieri, E.

“…Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of differentiated thyroid cancer (DTC) formulated by the European…”
Get full text

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18 by Voltin, C.-A., Goergen, H., Baues, C., Fuchs, M., Mettler, J., Kreissl, S., Oertl, J., Klaeser, B., Moccia, A., Drzezga, A., Engert, A., Borchmann, P., Dietlein, M., Kobe, C.

“…Bone marrow (BM) involvement defines advanced-stage Hodgkin lymphoma and thus has impact on the assignment to treatment. Our aim was to evaluate whether the…”
Get full text

Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels by Hohberg, M., Kobe, C., Täger, P., Hammes, J., Schmidt, M., Dietlein, F., Wild, M., Heidenreich, A., Drzezga, A., Dietlein, M.

“…Purpose Our aim was to evaluate the benefit of early (1 h post-injection (p.i.)) and late (3 h p.i.) [ 68 Ga]PSMA-HBED-CC positron emission tomography…”
Get full text

Guidelines for radioiodine therapy of differentiated thyroid cancer by Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., Bombardieri, E.

Get full text

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group by Ferdinandus, J., Moccia, A. A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Fuchs, M., Behringer, K., Schneider, G., Rosenwald, A., Klapper, W., Eich, H. T., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A., Borchmann, P.

Get full text

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL by Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Ferdinandus, J., Fuchs, M., Rosenwald, A., Klapper, W., Eich, H., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A.

Get full text

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib by Bos, M, Gardizi, M, Schildhaus, H.U, Heukamp, L.C, Geist, T, Kaminsky, B, Zander, T, Nogova, L, Scheffler, M, Dietlein, M, Kobe, C, Holstein, A, Maintz, D, Büttner, R, Wolf, J

“…Abstract A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy…”
Get full text

Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma—results for dedicated assessment criteria in a blinded dual-centre read by Furth, C., Amthauer, H., Hautzel, H., Steffen, I.G., Ruf, J., Schiefer, J., Schönberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., Dietlein, M., Kobe, C.

“…The aim of this study was to evaluate the use and reliability of the new positron emission tomography (PET)-based response criteria for interim positron…”
Get full text

The implications of 18F-FDG PET for the diagnosis of endoprosthetic loosening and infection in hip and knee arthroplasty: results from a prospective, blinded study by Delank, K-St, Schmidt, M, Michael, J W-P, Dietlein, M, Schicha, H, Eysel, P

“…The most frequent complications of joint arthroplasty are septic or aseptic loosening of endoprostheses. Preoperative differentiation is essential, since very…”
Get full text

FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value by Markova, J., Kobe, C., Skopalova, M., Klaskova, K., Dedeckova, K., Plütschow, A., Eich, H.T., Dietlein, M., Engert, A., Kozak, T.

“…Background: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the…”
Get full text

[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer by Vallböhmer, D., Hölscher, A.H., Schneider, P.M., Schmidt, M., Dietlein, M., Bollschweiler, E., Baldus, S., Alakus, H., Brabender, J., Metzger, R., Mönig, S. P.

“…Background and Objectives Neoadjuvant chemotherapy is applied to improve the prognosis of patients with advanced gastric cancer. However, only a major…”
Get full text

Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results by Dietlein, M, Weber, K, Gandjour, A, Moka, D, Theissen, P, Lauterbach, K W, Schicha, H

“…Decision analysis is used here to establish the most cost-effective strategy for management of potentially operable non-small cell lung cancers (NSCLCs). The…”
Get full text

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective by Mernagh, P, Campbell, S, Dietlein, M, Luster, M, Mazzaferri, E, Weston, A R

“…Objective: This investigation evaluated the cost-effectiveness of radioiodine remnant ablation following preparation with recombinant human TSH (rhTSH),…”
Get full text

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy? by Kobe, C, Eschner, W, Sudbrock, F, Weber, I, Marx, K, Dietlein, M, Schicha, H

“…This study was performed to determine the results of ablative radioiodine therapy (RIT) when the achieved dose in the thyroid was above 200 Gy and to…”
Get more information

MIBI scintigraphy in hypofunctioning thyroid nodules--can it predict the dignity of the lesion? by Theissen, P, Schmidt, M, Ivanova, T, Dietlein, M, Schicha, H

“…Several authors have investigated the value of technetium-MIBI scanning to predict the dignity of hypofunctioning, cold thyroid nodules (HTN) in regions with…”
Get more information

EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL by Borchmann, P., Goergen, H., Kobe, C., Eichenauer, D., Greil, R., Lohri, A., Novak, U., Markova, J., Beck, H., Meissner, J., Zijlstra, J.M., Ostermann, H., Feuring‐Buske, M., Dierlamm, J., Eich, H., Baues, C., Rosenwald, A., Fuchs, M., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A.

Get full text

Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer by Schneider, C, Dietlein, M, Eschner, W, Schmidt, M, Kahraman, D, Kobe, C

“…Follicular thyroid cancer with thyroid hormone secreting metastases is an extremely rare condition, with only a few cases reported world-wide. We here present…”
Get more information

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3) by Dietlein, M, Dressler, J, Eschner, W, Grünwald, F, Lassmann, M, Leisner, B, Luster, M, Moser, E, Reiners, Chr, Schicha, H, Schober, O

“…The procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer (version 3) is the counterpart to the procedure guideline for (131)I…”
Get more information

Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size by Meixner, M, Hellmich, M, Dietlein, M, Kobe, C, Schicha, H, Schmidt, M

“…T stage was redefined for patients with differentiated thyroid carcinoma (DTC) between the 5th and 7th versions of the UICC tumour classification system. 636…”
Get more information

Guideline for radioiodine therapy for benign thyroid diseases (version 4) by Dietlein, M, Dressler, J, Grünwald, F, Leisner, B, Moser, E, Reiners, Chr, Schicha, H, Schneider, P, Schober, O

“…Version 4 of the guideline for radioiodine therapy for benign thyroid diseases includes an interdisciplinary consensus on decision making for antithyroid…”
Get more information